EG.5.1.8 with S:V83T (66 seqs, mainly in New Zealand, 5 countries)

[NkRMnZr]

Transferred from sars-cov-2-variants/lineage-proposals#1052

Defining Mutations: EG.5.1.8 > C12100G > C27603T > G21809A(S:V83T, on top of existing S:V83A/T21810C)
Query: C12100G, G21809A, C27603T
Earliest seq: 2023-08-26 (EPI_ISL_18231674, Canterbury, New Zealand)
Latest seq: 2023-11-09 (EPI_ISL_18523811, Ontario, Canada)
Sampled Countries: New Zealand (55), Australia (6: NSW/5; WA/1), Canada (3: ON/2; BC/1), Denmark (1), USA (1: UT)

Genomes:

EPI_ISL_18231674, EPI_ISL_18292098, EPI_ISL_18292173, EPI_ISL_18292409, EPI_ISL_18324404, EPI_ISL_18347440, EPI_ISL_18347535, EPI_ISL_18347670, EPI_ISL_18351514, EPI_ISL_18381760, EPI_ISL_18411408, EPI_ISL_18459103, EPI_ISL_18459109, EPI_ISL_18459137, EPI_ISL_18459157, EPI_ISL_18459184, EPI_ISL_18459194, EPI_ISL_18459198, EPI_ISL_18459202, EPI_ISL_18459238, EPI_ISL_18459264, EPI_ISL_18459278, EPI_ISL_18459281, EPI_ISL_18459314, EPI_ISL_18459331, EPI_ISL_18459361, EPI_ISL_18459368, EPI_ISL_18459391, EPI_ISL_18459400, EPI_ISL_18459414-18459415, EPI_ISL_18459446, EPI_ISL_18459506, EPI_ISL_18459568-18459569, EPI_ISL_18459591, EPI_ISL_18459662, EPI_ISL_18459665-18459666, EPI_ISL_18459675, EPI_ISL_18459695, EPI_ISL_18459717, EPI_ISL_18459758-18459760, EPI_ISL_18459765, EPI_ISL_18459769, EPI_ISL_18459771, EPI_ISL_18459774, EPI_ISL_18459807, EPI_ISL_18459822, EPI_ISL_18459867, EPI_ISL_18459872, EPI_ISL_18459902, EPI_ISL_18459958, EPI_ISL_18470418, EPI_ISL_18488262, EPI_ISL_18488283, EPI_ISL_18488324, EPI_ISL_18488327, EPI_ISL_18513580, EPI_ISL_18513826, EPI_ISL_18513832, EPI_ISL_18513834, EPI_ISL_18518811, EPI_ISL_18523811

UShER:
https://nextstrain.org/fetch/genome.ucsc.edu/trash/ct/subtreeAuspice1_genome_328bb_f133a0.json?f_userOrOld=uploaded%20sample&label=id:node_3481744

Trivia:

• Modifies S:V83A/T21810C inherited from BJ.1, 5'-end donor of XBB
• Could it form the N-linked glycosylation with S:N81? And, could JG.3+S:A83S(31 seqs, 6 countries) #2363 (with S:V83S, already desgnated as JG.3.3) have similar effect?
• Around 5% prevalence in NZL (Cov-Spectrum)
  

[NkRMnZr]

Designated as KB.3 (EG.5.1.8.3) via 682de0e